![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » GLIVEC RECEIVES POSITIVE EUROPEAN UNION OPINION FOR TREATMENT OF RARE, POTENTIALLY LIFE-THREATENING CANCERS WITH LIMITED TREATMENT OPTIONS
GLIVEC RECEIVES POSITIVE EUROPEAN UNION OPINION FOR TREATMENT OF RARE, POTENTIALLY LIFE-THREATENING CANCERS WITH LIMITED TREATMENT OPTIONS
July 31, 2006
Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion for the use of Glivec (imatinib)[1] as a treatment for the solid tumor dermatofibrosarcoma protuberans (DFSP) and for hematologic malignancy Philadelphia chromosome-positive (Ph+) acute lymphocytic leukemia (ALL).
MBL.is (http://www.mbl.is/mm/vidskipti/hugin_news.html?id=1066400)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct